Mitochondrial Encephalopathy Caused by a New Biallelic Repeat Expansion 

Scientists uncover a new biallelic GGGCC repeat expansion leading to NAXE-related mitochondrial encephalopathy in a three-year-old patient

Short tandem DNA repeat expansions are known to cause several mitochondrial disorders that most frequently affect the central nervous system. In this study, researchers from Japan evaluated a patient cohort with undiagnosed mitochondrial diseases using long read sequencing and genetic analysis. They identified a three-year-old girl with mitochondrial encephalopathy having biallelic GGGCC repeats in the NAXE promoter region, highlighting the importance of modern technologies in the genetic evaluation of novel repeat expansions.

Mitochondrial diseases are among the most prevalent hereditary metabolic disorders, known to occur in one out every 5000 births. Single nucleotide variations, indels, and structural variations are known to cause these disorders. While many arise from single nucleotide variations, indels, or structural variants, some forms are also triggered by repeat expansions in nuclear genes affecting mitochondrial function, which can result in severe mitochondrial dysfunction. These diseases often impact the central nervous system (CNS), and mitochondrial encephalopathies represent a subset characterized by prominent CNS lesions. 

In a new study published in npj Genomic Medicine on October 25, 2024, a research team led by Professor Yasushi Okazaki, along with Dr. Kei Murayama and Dr. Yukiko Yatsuka, from the Division of Diagnostics and Therapeutics of Intractable Diseases at the Intractable Disease Research Center in Juntendo University, Japan used advanced techniques to identify a biallelic GGGCC repeat expansion that caused NAXE-related mitochondrial encephalopathy in a three-year-old girl. An autosomal recessive hereditary disorder, NAXE-related mitochondrial encephalopathy is characterized by biallelic pathogenic variants in NAD(P)HX epimerase, which leads to accumulation of a toxic metabolite that damages mitochondrial function resulting from a deficiency in the enzyme.

Prof. Okazaki, who led this study, explains, “As part of our strategy to achieve molecular diagnoses on 2,932 undiagnosed patients with mitochondrial diseases in Japan, we conducted RNA sequencing of samples from fibroblasts obtained from 400 patients, in addition to genomic sequencing.” Of these patients, 303 were biochemically confirmed to have mitochondrial disorders and the team performed bioinformatics analysis to isolate individuals with marked dysregulation of candidate causative genes. It is then that the case of a three-year-old girl with severely reduced NAXE gene expression was discovered. This patient did not report a familial history of mitochondrial, rare, or neurodegenerative diseases, but clinically presented with truncal instability while sitting, mild psychomotor developmental delay, seizure, and difficulty hearing in the right ear. Using long read sequencing, the team found almost 200 repeats of GGGCC in the patient’s NAXE promoter region, compared to just three repeats in the reference sequence!

The team analyzed the unspliced NAXE transcripts from this patient to examine the molecular mechanism underlying the severe reduction in NAXE transcripts and protein. They found that transcriptional suppression occurred due to hypermethylation of the repeat regions in the NAXE promoter regions. Further, they also observed hypermethylation on the repeat regions in one of the alleles in the patient’s mother. The mother’s allele with the normal range of repeats were not hypermethylated, however. Genetic analysis of the patient’s sample demonstrated that the homozygosity of the repeat expansion is due to the maternal chromosome 1 uniparental disomy (UPD), an abnormal condition where both members of a chromosome pair are inherited from one parent. 

Prof. Okazaki adds, “We also performed amplicon long read sequencing on 242 samples to identify other pathogenic variants for NAXE-related mitochondrial encephalopathy and found several variants. However, further studies will be needed to evaluate the pathogenicity of these variants.” Pathogenic repeat expansions often cause cytotoxicity resulting from translated peptide accumulation. However, in this case of GGGCC repeat expansion in NAXE, NAXE mRNA was extremely decreased, suggesting that it could minimize the impacts of such mechanisms. 

Prof. Okazaki points out a few limitations in their study that could open up scope for further research. “We found only a single case of repeat expansion in the pedigree, warranting further investigations in more cohorts. Our experiments to identify pathogenic GGGCC repeat expansions involved polymerase chain reaction (PCR)-based techniques, so we could have overlooked PCR-resistant structural variants of such repeats. Also, we have not tried to measure the toxic metabolites like cyclic NADHX, which is a direct consequence of the dysfunction of NAD(P)HX epimerase encoded by NAXE,” he highlights.

Overall, the study emphasizes the importance of advanced sequencing technologies in identifying previously unknown genetic causes of mitochondrial diseases, suggesting that UPD, which occurs in approximately 0.05% of live births, could play a significant role in homozygosity for rare repeat expansions and help diagnose patients. Hopefully, further research can help reveal the pathogenicity of other potential NAXE variants, allowing researchers to investigate the occurrence of GGGCC expansions in larger patient cohorts.

Reference

Title of original paper: Biallelic GGGCC Repeat Expansion leading to NAXE-related Mitochondrial Encephalopathy

Journal: npj Genomic Medicine 

DOI: https://doi.org/10.1038/s41525-024-00429-5

Authors: Kokoro Ozaki ^1,2,12, Yukiko Yatsuka ^2,12, Yoshinobu Oyazato³, Atsushi Nishiyama³, Kazuhiro R. Nitta², Yoshihito Kishita^2,4, Takuya Fushimi⁵, Masaru Shimura⁵, Shohei Noma¹, Yohei Sugiyama⁶, Michihira Tagami¹, Moe Fukunaga¹, Hiroko Kinoshita¹, Tomoko Hirata¹, Wataru Suda⁷, Yasuhiro Murakawa⁸, Piero Carninci^9,10, Akira Ohtake¹¹, Kei Murayama^2,5, and Yasushi Okazaki ^1,2 

Affiliations: 

¹Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

²Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Japan

³Department of Pediatrics, Kakogawa Central City Hospital, Japan

⁴Department of Life Science, Faculty of Science and Engineering, Kindai University, Japan

⁵Center for Medical Genetics and Department of Metabolism, Chiba Children’s Hospital, Japan

⁶Department of Pediatrics, Faculty of Medicine, Juntendo University, Japan

⁷Laboratory for Symbiotic Microbiome Sciences, RIKEN Center for Integrative Medical Sciences, Japan

⁸RIKEN-IFOM Joint Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Japan

⁹Laboratory for Transcriptome Technology, RIKEN Center for Integrative Medical Sciences, Japan

¹⁰Human Technopole, via Rita Levi Montalcini 1, Milan, Italy

¹¹Department of Clinical Genomics and Pediatrics, Faculty of Medicine, Saitama Medical University, Japan

¹²These authors contributed equally: Kokoro Ozaki, Yukiko Yatsuka

About Professor Yasushi Okazaki

Professor Yasushi Okazaki is the Director of Juntendo University’s Intractable Disease Research Center in Japan. He is also the Team Lead at the Laboratory for Comprehensive Genomic Analysis at the RIKEN Center for Integrative Medical Sciences, Japan. Prof. Okazaki completed his M.D. from Okayama University Medical School in 1986, followed by a Ph.D. in Medical Informatics from Osaka University Medical School in 1995. His main research interests are in the fields of genomic medicine, clinical genetics, mitochondrial and cardiovascular diseases, bioinformatics, cancer genetics, and regenerative therapy. He is part of over 600 research articles, with more than 33,000 citations.